Kornimate/medical-research-clean huggingface dataset:
elucidating the genetic basis of the pleuropulmonary blastoma (ppb) familial cancer syndrome

Conditions: Pleuropulmonary Blastoma; Cystic Nephroma; Sertoli-Leydig Cell Tumor of Ovary; Medulloepithelioma; Embryonal Rhabdomyosarcoma of Cervix; Goiter; Sarcoma; Pineoblastoma; Pituitary Tumors; Wilms Tumor

Summary: pleuropulmonary blastoma (ppb) is a rare lung tumor which develops in childhood. the underlying genetic factors which contribute to the development and progression of ppb are not defined. we are working to identify the genetic factors which may contribute to the development of this rare tumor.

studies of inherited cancer syndromes have provided unique opportunities to uncover and explain important cellular pathways with broad relevance to both sporadic cancers and human development. this proposal studies the cancer predisposition syndrome originally described as a familial form of pleuropulmonary blastoma (ppb). ppb is a rare, aggressive lung cancer that affects young children. children with ppb and/or their family members are at increased risk for a number of rare conditions, including wilms tumor, rhabdomyosarcoma, brain tumors, ovarian tumors and nodular hyperplasia of the thyroid gland. in 2009, we mapped a ppb locus and identified germline, loss of function mutations in one copy of dicer1 as the genetic basis of this syndrome. dicer1 encodes a protein that performs the final critical step in maturation of micrornas (mirnas). mirnas are an important form of gene regulation. the syndrome's varied nature is likely attributable to the various roles of mirnas during different developmental and/or functional circumstances. this study focuses on defining the full phenotype of this cancer predisposition syndrome including penetrance, expressivity in children and adults, pathologic classification of disease and spectrum of predisposing dicer1 mutations. improved understanding of the clinical and genetic features of this cancer predisposition syndrome is essential to facilitate early diagnosis when the diseases are most curable, and to create genetic counseling and educational materials to guide medical care.

Eligibility criteria:
inclusion criteria: * child or adult diagnosed with pleuropulmonary blastoma, cystic nephroma, embryonal rhabdomyosarcoma of uterine cervix, ovarian sertoli-leydig tumor or gynandroblastoma, pineoblastoma, pituitary blastoma, nasal chondromesenchymal hamartoma, medulloepithelioma, wilms tumor, germline or mosaic dicer1 mutation exclusion criteria: * child or adult who does not fit inclusion criteria as listed above

Keywords: pleuropulmonary blastoma ppb cystic nephroma dicer1 mirna
a research study to compare two kinds of daily headache

Conditions: Migraine

Summary: chronic daily headache has been classified into several categories. one category is of sudden onset and is called new daily persistent headache (ndph). another category of daily headache evolves gradually and is called transformed migraine (tm). this research study is being conducted to compare people with these two kinds of daily headache in order to improve our understanding of these conditions.


Eligibility criteria:
inclusion criteria: * male and female patients aged 14-65, inclusive * diagnosis of ndph or tm according to the silberstein-lipton criteria. * ability to read and understand an informed consent form and study procedures exclusion criteria: * pregnancy * subjects with any disease or condition that would result in unreliable data or confound the data obtained for this study, as determined by the principal investigator.
cognitive behavioral therapy plus drug treatment for obsessive compulsive disorder

Conditions: Obsessive-Compulsive Disorder

Summary: this study will evaluate the effectiveness of two cognitive behavioral therapies (cbts) in treating obsessive compulsive disorder (ocd) in patients who are taking medication but still have residual symptoms.

participants remain on their current ocd medication and are randomly assigned to receive one of two cbts: exposure and ritual prevention or stress management therapy. exposure and ritual prevention involves imaginal and in-vivo exposure and requires that participants refrain from ritualizing. stress management involves relaxation, assertiveness training, and structured problem-solving. therapy occurs twice per week for 2 months. participants are assessed verbally by an independent evaluator and are asked to complete self-rating forms. patients who respond are followed for up to 1 additional year. participants continue to take the same medication and the same monthly therapy for the first 6 months of follow-up. during the second 6 months of follow-up, participants discontinue therapy but continue taking the same medication. for information on a related study, please follow this link: http://clinicaltrials.gov/show/nct00389493

Eligibility criteria:
inclusion criteria: * obsessive-compulsive disorder (ocd) diagnosis * currently taking a serotonin reuptake inhibitor (sri, i.e. clomipramine, fluoxetine, fluvoxamine, paroxetine, sertraline, or citalopram) for ocd exclusion criteria: * medical or psychiatric conditions that would make participation in the study hazardous * intensive cognitive-behavioral therapy while on an adequate dose and duration of an sri for ocd

Keywords: cognitive behavioral therapy
a clinical study of furmonertinib in the treatment of egfr-mutated nsclc with leptomeningeal metastases

Conditions: Lung Cancer (NSCLC); Leptomeningeal Cancer

Summary: this study adopts a retrospective design. patients enrolled will include those who received furmonertinib (treatment duration ≥1 month) between march 3, 2021, and december 31, 2024, with concurrent therapies permitted (e.g., radiotherapy, intrathecal chemotherapy, surgical interventions such as ventriculoperitoneal shunting). a retrospective analysis will be conducted to investigate the efficacy and safety of furmonertinib-based therapy (with or without other treatments) in egfr-mutated nsclc patients with leptomeningeal metastasis.


Eligibility criteria:
inclusion criteria: 1. patients aged ≥18 years, male or female; 2. histologically or cytologically confirmed diagnosis of \*\*non-small cell lung cancer (nsclc); 3. " egfr mutation-positive"(classic or non-classic mutations) confirmed by genetic testing; 4. "leptomeningeal metastasis" definitively diagnosed by investigators based on "eano-esmo diagnostic criteria", involving comprehensive clinical assessment including symptom evaluation, imaging evaluation (mri/ct), and/or cerebrospinal fluid (csf) cytology; 5. received furmonertinib (treatment duration ≥1 month) between "march 3, 2021, and december 31, 2024", with concurrent therapies permitted (e.g., radiotherapy, intrathecal chemotherapy, surgical interventions such as ventriculoperitoneal shunting). exclusion criteria 1. history of other malignancies during nsclc treatment or prior to diagnosis, except those effectively controlled (e.g., complete remission ≥5 years); 2. severe gastrointestinal disorders affecting drug administration or absorption, including but not limited to peptic ulcer disease, inflammatory bowel disease, or malabsorption syndromes; 3. evidence of uncontrolled systemic diseases (e.g., uncontrolled hypertension \[bp \>140/90 mmhg despite treatment\], diabetes mellitus \[hba1c \>8%\], arrhythmias, heart failure \[nyha class iii/iv\], active bleeding, active infections requiring iv antibiotics, or interstitial pneumonia requiring corticosteroid therapy), which in the investigator's judgment may directly compromise patient prognosis; 4. incomplete medical records or follow-up data; 5. pregnancy or lactation; 6. other severe acute/chronic medical conditions, psychiatric disorders, or laboratory abnormalities that, in the investigator's opinion, may confound the interpretation of study results.
comparison between two methods of bilateral stenting for malignant hilar obstruction

Conditions: Bile Duct Neoplasm; Obstructive Jaundice

Summary: internal biliary drainage using stent is used for malignant hilar obstruction such as cholangiocarcinoma, hepatocellular carcinoma and other malignancy including metastasis. bilateral drainage is more physiologic and have more long patency than unilateral drainage. there are two methods of bilateral drainage: y-stent and side by side. however there are no clinical data about comparing the effectiveness of these two methods. therefore the investigators want to compare the clinical outcomes of two methods: y-stent and side by side.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * patient who have obstructive jaundice (bilirubin \> 2.0mg/dl) due to hilar malignancy exclusion criteria: * patients with endoscopic retrograde cholangiogram is not possible * bleeding tendency (pt inr \> 1.5, platelet \< 50,000) * poor general condition (ecog 3-4) or cardiopulmonary deterioration * pregnancy
a compassionate treatment protocol for the use of trimetrexate glucuronate (neutrexin) with leucovorin protection for european adult patients (>= 13 years old) with pneumocystis carinii pneumonia

Conditions: Pneumonia, Pneumocystis Carinii; HIV Infections

Summary: to evaluate the safety and efficacy of trimetrexate glucuronate with leucovorin protection in european patients with pneumocystis carinii pneumonia (pcp) who are refractory to or have demonstrated severe or life-threatening toxicities to standard therapies (e.g., tmp/smx or parenteral pentamidine).

patients receive intravenous infusions of trimetrexate glucuronate and leucovorin for 21 days. leucovorin is continued for 3 additional days after discontinuation of trimetrexate glucuronate. patients are followed for 1 month.

Eligibility criteria:
inclusion criteria patients must have: * pneumocystis carinii pneumonia (pcp) confirmed within 15 days prior to study entry. * serious intolerance and/or resistance to standard therapies (such as trimethoprim/sulfamethoxazole and parenteral pentamidine) during the course of therapy for the current episode of pcp, or a documented history of such intolerance during a prior episode. * consent of parent or guardian if less than 18 years of age. exclusion criteria patients with the following prior conditions are excluded: history of type i hypersensitivity (i.e., urticaria, angioedema, or anaphylaxis), exfoliative dermatitis, or other life-threatening reactions due to trimetrexate glucuronate.

Keywords: trimetrexate pneumonia, pneumocystis carinii leucovorin drug therapy, combination acquired immunodeficiency syndrome
intraoperative intraportal chemotherapy combined with adjuvant chemotherapy for stage ii and iii colorectal cancer

Conditions: Colorectal Neoplasms; Neoplasm Metastasis; Liver Neoplasms

Summary: in this study, the investigators assessed whether intraoperative intraportal infusion of 5-fu and oxaliplatin is able to prevent liver metastasis in patients receiving curative colorectal cancer resection.

in this study, the investigators assessed whether intraoperative intraportal infusion of 5-fu and oxaliplatin is able to prevent liver metastasis and improve survival in patients with stage ii or stage iii colorectal cancer without apparent liver metastasis based on a thorough preoperative evaluation. patients with stage ii or stage iii colorectal cancer (crc) were randomly assigned to two arms.arm a: 5-fu 1g and oxaliplatin 100mg + curative resection (study group, n=132). arm b: curative resection alone (control group, n=132).follow-up: x-ray, us, ct, blood test, colonoscopy,every 3months. the study endpoints were disease-free survival, overall survival, and liver metastasis-free survival as evaluated by intent-to-treat analysis.

Eligibility criteria:
inclusion criteria 1. age ≥ 18 and ≤ 75 years and with histologically proven adenocarcinoma of the colon or rectum 2. who performance status of 0 or 1 3. stage ii (t3-4, n0, m0) or stage iii (t0-4, n1-2, m0) disease (according to the 1997 revision of the international union against cancer tnm staging system) as determined by a preoperative evaluation that included colonoscopy and an abdominal computed tomography (ct) scan 4. written informed consent for participation in the trial. exclusion criteria 1. has prior other malignant cancer 2. has severe major organ dysfunction 3. has prior cancer therapy before surgery

Keywords: colorectal neoplasms liver neoplasm metastasis tegafur oxaliplatin
a study to investigate the safety, tolerability and pharmacokinetics of suvn-911 in healthy subjects

Conditions: Depressive Disorder, Major

Summary: this is a phase 1, conventional, double-blind, placebo-controlled, single-center clinical study comprised of 2 segments (segment 1 and segment 2) in which single and multiple doses of suvn-911 or placebo will be orally administered to healthy male subjects to evaluate the safety, tolerability, and pharmacokinetic profile.

this is a single and multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of suvn-911 administered orally once a day to healthy male subjects. the study will be conducted under double-blind conditions. the primary objectives are to evaluate the safety and tolerability of suvn-911 following oral administration of single or multiple ascending doses and estimate the maximum tolerated dose of suvn-911, if possible. the secondary objectives are to evaluate the single and repeat dose plasma and urine pharmacokinetics of suvn-911 following oral administration of single and multiple ascending doses in healthy male subjects.

Eligibility criteria:
inclusion criteria: * healthy male aged 18 to 45 years with a body mass index (bmi) between 18 and 30 kg/m2, (inclusive). exclusion criteria: * standard exclusion criterion for phase 1 clinical trial in healthy subjects: * history of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate. * history or presence of gastro intestinal (gi), hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs as judged by investigator.

Keywords: suvn-911 depression single dose multiple dose alpha4 beta2 receptor first in human safety pharmacokinetics tolerability
patient monitoring in the intensive care unit

Conditions: Medical Informatics; Intensive Care

Summary: a cross-sectional survey of nurses' perception of patient monitoring in the icus


Eligibility criteria:
inclusion criteria: * registered nurses in the icus exclusion criteria: -
safety and efficacy of obatoclax mesylate (gx15-070ms) in combination with bortezomib for the treatment of relapsed or refractory mantle cell lymphoma (mcl)

Conditions: Mantle-Cell Lymphoma

Summary: defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogenic signal is present. obatoclax is designed to restore apoptosis through inhibition of the bcl-2 family of proteins, thereby reinstating the natural process of cell death that is often inhibited in cancer cells.

this is a multi-center, open-label, phase i study of obatoclax administered in combination with bortezomib in 3-week cycles to patients with relapsed or refractory mantle cell lymphoma. treatment may be administered on an outpatient basis. no investigational or commercial agents or therapies other than those described herein may be administered with the intent to treat the patients's malignancy. supportive care measures including those directed at controlling symptoms resulting from mantle cell lymphoma are allowed.

Eligibility criteria:
inclusion criteria: * pathological confirmation of mantle cell lymphoma (ml) * must have documented relapse or progression following 1 or 2 prior lines of antineoplastic therapy * must have normal organ function * must have the ability to understand and willingness to sign a written informed consent form exclusion criteria: * no other agents or therapies administered with the intent to treat malignancy * patients with prior exposure to obatoclax * uncontrolled, intercurrent illness * pregnant women and women who are breast feeding
baclofen treatment of ataxia telangiectasia

Conditions: Ataxia Telangiectasia

Summary: this research is being done to find out if baclofen, a medicine that is often used for the treatment of abnormal stiffness, might also be useful to treat some of the neurologic problems caused by ataxia telangiectasia (a-t). the investigators also want to find out if there are better ways to measure the problems of ataxia and abnormal eye movement for future studies of medication in ataxia telangiectasia.


Eligibility criteria:
inclusion criteria: * teenagers over 12 years old and young adults with a-t may join if they have been evaluated previously in the a-t clinical center at johns hopkins hospital and have a measurable abnormality of eye movement. * patients who are presently taking baclofen will be eligible for the study if they are presently receiving the medication under the direction of dr. crawford in the atcc, and are willing to withdraw from the medication for a period of one month prior to the initial screening visit. * female patients who are sexually active will be given a standard serum hcg pregnancy test. * those who are sexually active will be counseled about necessary precautions against pregnancy during the duration of the trial. exclusion criteria: * a positive pregnancy test.

Keywords: at ataxia telangiectasia
association between plasma melatonin and no-reflow

Conditions: ST-segment Elevation Myocardial Infarction

Summary: st-segment elevation myocardial infarction (stemi) is an acute manifestation of coronary heart disease, remaining a frequent cause of death. a better understanding of risk factors and pathogenic mechanisms underlying stemi may help improve the prognosis and life quality of these patients. melatonin is the chief indoleamine produced by the pineal gland, and a well-known antioxidant and free radical scavenger. basic studies have showed that melatonin is associated with myocardial infarction and heart failure. however, no study has evaluated whether melatonin is associated with adverse clinical outcomes in stemi patients.


Eligibility criteria:
inclusion criteria: a diagnosis of stemi and needed pci exclusion criteria: patients with cancer patients who used melatonin

Keywords: melatonin stemi no-reflow
quality of life assessment in patients undergoing prolonged suppressive antibiotherapy for prosthetic joint infection.

Conditions: Prosthetic Joint Infection

Summary: prosthetic joint infection (pji) management is complex and requires prosthesis replacement when symptoms duration is greater than 30 days or debridement with modular set replacement when symptoms duration is lesser than one month. nevertheless, the prolonged suppressive antibiotherapy (psa) is the single treatment we can provide to high risk surgical patients and those who refuse reoperation. there is limited data available on psa modality, its tolerance and efficacy, this lack of data motivated us to concept a prospective study of long term patient follow up with pji treated with prolonged suppressive antibiotherapy.

main objective: quality of life assessment of patients undergoing prolonged suppressive antibiotherapy for pji. secondary objectives: 1. depressive symptoms assessment in patients undergoing prolonged suppressive antibiotherapy for pji. 2. functional assessment in patients undergoing prolonged suppressive antibiotherapy for pji. 3. evaluation of psa side effects 4. evaluation of nutritional status 5. evaluation of of psa termination criteria methods: the follow up oh this cohort will be conducted using 3 questionaries related to quality of life, joint stiffness and depressive symptoms. study type: this is a study of health care procedure, evaluating the quality of life of patients undergoing prolonged suppressive antibiotherapy for pji. sample size: all patients cared by our referral center of bone and joint infection, who meet protocol selection criteria will be included in the study, thus we are expecting to recruit 60 patients. study duration: 6 years. recruitment period: 4 years. maximal duration of data collection: 2 years. investigator center: single center study. mean patient inclusion per year: 15 patients per year.

Eligibility criteria:
inclusion criteria: * patient aged over 18 years old with hip or knee prosthetic infection who consented to participate in the study * non-eligible patient to surgical treatment * patient eligible to prolonged suppressive antibiotherapy exclusion criteria: * patient who does not meet eligibility criteria * patient living or traveling abroad for whom 2 years minimum follow up is impossible. * patient lawfully deprived of his liberty * patient not insured under social security scheme
management of labor in patients with previous cesarian section

Conditions: Pregnancy; Previous Cesarian Section; Premature Rupture of Membranes (PROM)

Summary: induction of labor in women desiring tolac has long been a topic of controversy. the paucity of published data on mechanical cervical ripening in the setting of tolac and term prom has led us to undertake the present clinical trial.


Eligibility criteria:
inclusion criteria: * diagnosed to be pregnant with prom at \>34 weeks. rupture of membranes will be determine clinically and confirmed by positive nitrazine test. * ruptured membranes have occurred in the last 24 hours prior to inclusion in the study. * found to have an unripe cervix in a speculum examination. * singleton pregnancy in a vertex presentation well applied to the cervix and absence of significant and regular uterine contractions (3-5/10 min) * previous on cesarian section. * willingness to comply with the protocol for the duration of the study. * have signed an informed consent. exclusion criteria: patients having any of the following conditions: * any contraindication for the vaginal delivery (i.e. placenta previa, non vertex presentation). * regular uterine contractions (3-5/10 min). * diagnosis of rupture membranes was made over 24 hours prior the study inclusion. * evidence of chorio-amnionitis (t 37.6 celsious degree with uterine tenderness and maternal or fetal tachycardia or purulent discharge or wbc\>/=20,000) * suspected placental abruption or presence of a significant hemorrhage. * non-reassuring fetal status (as determined by fetal heart rate monitoring and/or bio-physical profile) necessitating immediate intervention.

Keywords: tolac prom previous cesarian section mechanical cervical ripening